Psilocybin altered how brain activity and blood flow work together in Alzheimer’s mice, but not in healthy ones. This mismatch—called disrupted neurovascular coupling—could become a key biomarker for understanding how psychedelics interact with brain disorders. The study used live brain imaging to reveal these changes, offering early insights into psilocybin’s impact on Alzheimer’s-related brain function.